| Literature DB >> 35566283 |
Huan Chen1, Wanyu Wang2, Shiyang Yu1, Huimin Wang1, Zilu Tian1, Song Zhu1.
Abstract
Procyanidins, as a kind of dietary flavonoid, have excellent pharmacological properties, such as antioxidant, antibacterial, anti-inflammatory and anti-tumor properties, and so they can be used to treat various diseases, including Alzheimer's disease, diabetes, rheumatoid arthritis, tumors, and obesity. Given the low bioavailability of procyanidins, great efforts have been made in drug delivery systems to address their limited use. Nowadays, the heavy burden of oral diseases such as dental caries, periodontitis, endodontic infections, etc., and their consequences on the patients' quality of life indicate a strong need for developing effective therapies. Recent years, plenty of efforts are being made to develop more effective treatments. Therefore, this review summarized the latest researches on versatile effects and enhanced bioavailability of procyanidins resulting from innovative drug delivery systems, particularly focused on its potential against oral diseases.Entities:
Keywords: antioxidation; bioavailability; drug delivery; oral disease; procyanidins
Mesh:
Substances:
Year: 2022 PMID: 35566283 PMCID: PMC9104295 DOI: 10.3390/molecules27092932
Source DB: PubMed Journal: Molecules ISSN: 1420-3049 Impact factor: 4.927
Figure 1Structure, properties and therapeutic applications on oral diseases of procyanidins. Notes: Procyanidins, as an emerging pharmaceutical with multifunction, have versatile properties such as antioxidant activity, antibacterial activity, anti-inflammatory activity and antineoplastic activity. It has the capacity to therapy diverse oral diseases including oral cancer, periodontitis, dental caries, diseases of the oral mucosa, endodontic root canal; peri-implantitis and dental restoration.
Figure 2The anti-inflammation signal pathways of procyanidins. Notes: (1). Procyanidins activated the AMPK/Nrf2 pathway; targeted its downstream gene contributing to the increased level of antioxidant genes NQO1, HO-1 and γ-GCS. (2). Procyanidins inhibits the release of inflammatory factors IL-6, TNF-α, PGE2, NO through the IκB/NF-κB p65 pathway (Note: PCA1 show no effect of PEG2). (3). Procyanidins inhibit LPS activated AP-1/c-Jun pathway decreasing the gene expression of NLRP3, and suppress subsequent caspase-1 activation and the release of IL-1β. (4). Besides, Procyanidins can also lower the production of ROS, reverse decreased mitochondrial membrane potential, inhibit Ca2+ exclusion. Abbreviation: PCA1, procyanidins A1; PCA2, procyanidins A2; PCB2, procyanidins B2; AMPK, adenosine monophosphate-activated protein kinase; Nrf2, nuclear factor erythroid 2-related factor 2; NQO1, NAD(P)H quinone oxidoreductase 1; HO-1, heme oxygenase-1; γ-GCS, γ-glutamylcysteine synthetase; LPS, lipopolysaccharide; MAPK, mitogen-activated protein kinase; IKK, inhibitor of kappaB kinase; IκB, nuclear factor kappa-B; NF-κB, nuclear factor kappa-B; PGE2, prostaglandin E2; TNF-α, tumor necrosis factor-α; IL-6, Interleukin-6; JNK, c-Jun N-terminal kinases; ERK, extracellular signal-regulated kinase; NLRP3, NOD-like receptor family pyrin domain containing 3; IL-1β, Interleukin-1β; ROS, reactive oxygen species.
Figure 3The antineoplastic mechanism of procyanidins. Notes: (1). Procyanidins can inhibit cell proliferation by phosphorylated IGF-1R, which can activate cysteine proteases and accelerate the degradation of activated Nrf2. (2). B2G2 can inhibit stem cell self-renew process through inhibiting the activitation of Notch1 pathway. (3). GSP can reverse MDR by suppressing both MAPK/ERK/YB-1 and NF-κB p65 pathway. (4). PC1 inhibits EMT by inhibiting TGF-β-induced phosphorylation of Smad-2, and further down-regulates Snail, E-cadherin and fibronectin. (5). HEX can inhibit PI3K/Akt/GSK-3β and PI3K/Akt/Bad signaling pathways, and induce the mitochondrial apoptosis pathway of cancer cells. In addition, PCB2 also plays an anti-proliferative role and stimulates apoptosis, induces autophagy of cancer cells through the Akt/mTOR pathway. Abbreviation: IGF-1R, insulin-like growth factor 1 receptor; B2G2, B2 3;3″-di-O-gallate; MDR, multidrug resistance; GSP, grape seed procyanidins; P-gp, p-glycoprotein; YB-1, Y-box binding protein 1; EMT, Epithelial-to-mesenchymal transition; PC1, procyanidin C1; Hex, hexamer; Bcl-2, B-cell lymphoma-2.
The physico-chemical characters of different PCs delivery vehicles.
| Delivery System | Chemicals/Polymer Used | Preparation Methods | Size Range (nm) | Evaluations on the Encapsulated PCs | Effect | References |
|---|---|---|---|---|---|---|
| PLA nanoparticles | PLA | No data | 256 | Chemical stability | Sustained release of PCs from PLA nanoparticles. | [ |
| PLGA nanoparticles | PLGA | Nanoprecipitation | 195.4 ± 23.8 | Chemical stability | The biodegradation resistance of demineralized dentin was improved by loading collagen crosslinking agent into biodegradable polymer nanoparticles via dentin tubules. | [ |
| Polysaccharide-based nanoparticles | Chitosan; lauryl succinyl | Ionic gelation | 458 ± 11; 3640 ± 33 | In vitro cytotoxicity in HEK-293 cells | The encapsules of PCs reduce toxicity and improve chemical stability. | [ |
| Polysaccharide-based nanoparticles | chitosan | Hydrogen bond | 367.3–293.2 | Chemical stability; the ExPEC invasion of gut epithelial cells in vitro. | PCs inhibited invasion of gut epithelial cells by ExPEC. | [ |
| Polysaccharide-based nanoparticles | Gelatin; chitosan | Hydrogen bond; hydrophobic interaction and electrostatic interaction | 344.7 | Chemical stability; In vitro apoptotic; necrotic; and cytotoxic properties in THP-1 cells | The stability and biological activity of PCs were improved by nano encapsulation. | [ |
| Protein-based nanoparticles | Poly-lactic acid | Hydrogen bond | 256 | Chemical stability | The encapsulation of PCs effectively enhanced the antioxidant activity | [ |
| Protein-based nanoparticles | Zein | Hydrogen bond and hydrophobic interactions | 392–447 | Solubility; in vitro cytotoxicity in HL-60 cells | PCs-zein nanoparticles decreased the cytotoxicity of procyanidins in HL-60 cells | [ |
| Modified hydroxyapatite inorganic nanoparticles | Hydroxya-patite | Metal chelation | 20–50 | Chemical stability | Enhanced the colloidal stability of nHAp particles | [ |
| Metallic nanoparticles | Gold | Metal chelation | 20–25 | Chemical stability | PCs-gold nanoparticles can be used as biocompatible gold nanoparticles for medical applications; molecular imaging and cancer therapy. | [ |
| Metallic nanoparticles | Gold | Metal chelation | 20–40 | Chemical stability | PCs-gold nanoparticles might serve as anticancer agents in killing cancer. | [ |
| Metallic nanoparticles | Gold | Metal chelation | 6–24 | Stability and in-vitro methods employed in antidiabetic studies | PCs-gold nanoparticles have potential anti-diabetes and anti-oxidation effects. | [ |
| Metallic nanoparticles | Silver; gelatin | Metal chelation | 150–230 | Chemical stability; antibacterial assessment; cytotoxicity test | GSP/Gelatin Composite Fibers Contained Silver Nanoparticles had the potential for applications in antimicrobial tissue engineering and wound dressing. | [ |
| Metallic nanoparticles | Silver; chitosan | Metal chelation | 150 | Cytotoxicity patterns; the antipro-liferative activities; and the possible mechanisms of anticancer activity in HpG2 cells | The nanoparticles exhibited high anticancer activity against HpG2 cells and induced apoptosis by down-regulating Bcl2 gene and up-regulating p53. | [ |
| PUDL | Ultradeformable liposomes | Thin film hydration method | 140.6 ± 19 | Chemical stability | PUDL could increase the transdermalflux; prolong the release and improve the stability of PCs; and could serve as an effective dermal delivery system for procyanidins. | [ |
| SLN | Solid lipid | The melt-emulsion method | 243 | Chemical stability; evaluation of anti-oxidant activity | SLN loaded with GSP exhibit antioxidant effects for longer than free GSP. | [ |
Notes: PCs, procyanidins; GSP, grape seed procyanidins; PLGA, poly(lactic-co-glycolic acid); PLA, poly(D,L-lactic acid); ExPEC, extra-intestinal pathogenic Escherichia coli; Bcl-2, B-cell lymphoma-2; PUDL, ultradeformable liposomes; SLN, solid lipid nanoparticles.